Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (665)	5/29/1998 11:50:00 AM
From: Hong-Lee Yu	Read Replies (1) \| Respond to of 1686

Harold, Here is CVT-124 news CV Therapeutics CVT-124 Shows Renal Function In Phase II PALO ALTO, Calif. (Dow Jones)--CV Therapeutics Inc. (CVTX) said results of a recently completed Phase II trial indicated that its CVT-124 preserved glomerular filtration rate, a measure of renal function, in congestive heart failure patients. In a press release Friday, the company said CV-124 also increased sodium and urine excretion in the patients. CV Therapeutics said Biogen Inc. (BGEN) is evaluating CV-124 for treatment of congestive heart failure and the associated edema, under a license from CV Therapeutics. CV Therapeutics said the 12-patient, double-blind, placebo-controlled, Phase II trial studied the effect of a single intravenous dose of CVT-124 and furosemide on glomerular filtration rate, or GFR, the rate at which the kidney filters blood. The company said that in patients with moderate and moderately severe congestive heart failure, CVT-124 maintained GFR as compared to placebo. CV Therapeutics said the test also showed "clinically minimal but statistically significant" increases in potassium excretion. CVT-124 was generally well-tolerated by the patients. The company said it is in the process of completing the final study report. CV Therapeutics said the kidney's ability to filter blood is often already compromised in congestive heart failure patients, and the diminished output from the failing heart does not provide sufficient blood flow to the kidneys to support adequate filtration. As reported, in an 18-patient Phase II trial completed in October, CVT-124 caused "clinically useful and statistically significant" increases in urine, sodium and chloride excretion compared to placebo, according to the company. CV Therapeutics said CVT-124 has now been evaluated in over 70 U.S. subjects. Biogen, Inc. has exclusive worldwide rights to develop and sell CVT-124 and is funding all development and commercialization costs. CV Therapeutics discovers, develops and commercializes small molecule drugs to treat chronic cardiovascular diseases.